Corbus Pharmaceuticals Data on CRB-601 avĪ²8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting March 14, 2023
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update March 7, 2023
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA March 6, 2023
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) February 13, 2023
